According to the European and American guidelines in 2015, drug combination is reported as the treatment of choice for all hepatitis C genotypes. The response to treatment in non-cirrhotic patients of all genotypes was more than 95% within 12 weeks In studies conducted in Iran, 98% response to treatment was reported in cirrhotic patients with ribavirin (per-protocol) for 12 weeks. The drug side effects reported in this study were close to zero, and cold, pain and weakness were reported in some cases at the beginning of the treatment. Combining two drugs in one pill is not an easy task, as only Iran has produced this combination and SOVODAK is considered an Iranian initiative.